272 related articles for article (PubMed ID: 34679012)
1. Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect.
Heiat M; Hashemi Yeganeh H; Alavian SM; Rezaie E
Toxins (Basel); 2021 Oct; 13(10):. PubMed ID: 34679012
[TBL] [Abstract][Full Text] [Related]
2. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer.
Fleming BD; Ho M
Toxins (Basel); 2016 Sep; 8(10):. PubMed ID: 27669301
[TBL] [Abstract][Full Text] [Related]
3. Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update.
Fleming BD; Ho M
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32575752
[TBL] [Abstract][Full Text] [Related]
4. DT389-YP7, a Recombinant Immunotoxin against Glypican-3 That Inhibits Hepatocellular Cancer Cells: An In Vitro Study.
Hashemi Yeganeh H; Heiat M; Kieliszek M; Alavian SM; Rezaie E
Toxins (Basel); 2021 Oct; 13(11):. PubMed ID: 34822533
[TBL] [Abstract][Full Text] [Related]
5. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
[TBL] [Abstract][Full Text] [Related]
6. Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma.
Wang T; Zhang Q; Wang N; Liu Z; Zhang B; Zhao Y
Curr Med Chem; 2021; 28(16):3107-3146. PubMed ID: 33050856
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention.
Tian M; Shi Y; Liu W; Fan J
Sci China Life Sci; 2019 Sep; 62(9):1138-1143. PubMed ID: 31119560
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic use of immunotoxins.
Cobb PW; LeMaistre CF
Semin Hematol; 1992 Jul; 29(3 Suppl 2):6-13. PubMed ID: 1509295
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities.
Chen S; Cao Q; Wen W; Wang H
Cancer Lett; 2019 Sep; 460():1-9. PubMed ID: 31207320
[TBL] [Abstract][Full Text] [Related]
10. Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.
Ma Z; He H; Sun F; Xu Y; Huang X; Ma Y; Zhao H; Wang Y; Wang M; Zhang J
J Cancer Res Clin Oncol; 2017 Oct; 143(10):1929-1940. PubMed ID: 28536738
[TBL] [Abstract][Full Text] [Related]
11. [Construction, expression and targeting therapeutic of single-chain immunotoxin against hepatocellular carcinoma].
Zhang J; Liu YF; Yang SJ; Qiao Q; Cheng H; Ma FC; Chen WL
Zhonghua Gan Zang Bing Za Zhi; 2004 Mar; 12(3):148-50. PubMed ID: 15059298
[TBL] [Abstract][Full Text] [Related]
12. The application of nanoparticles in immunotherapy for hepatocellular carcinoma.
Hu X; Zhu H; He X; Chen J; Xiong L; Shen Y; Li J; Xu Y; Chen W; Liu X; Cao D; Xu X
J Control Release; 2023 Mar; 355():85-108. PubMed ID: 36708880
[TBL] [Abstract][Full Text] [Related]
13. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
14. Recombinant immunotoxins in targeted cancer cell therapy.
Reiter Y
Adv Cancer Res; 2001; 81():93-124. PubMed ID: 11430597
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor effect of recombinant immunotoxin EGF-TCS in nude mice bearing human hepatocellular carcinoma].
Yang HW; Yang HW; Li YM
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1535-6. PubMed ID: 17959515
[TBL] [Abstract][Full Text] [Related]
16. New Therapeutic Options for Advanced Hepatocellular Carcinoma.
Ma YS; Liu JB; Wu TM; Fu D
Cancer Control; 2020; 27(3):1073274820945975. PubMed ID: 32799550
[TBL] [Abstract][Full Text] [Related]
17. Immunotoxin: A new tool for cancer therapy.
Allahyari H; Heidari S; Ghamgosha M; Saffarian P; Amani J
Tumour Biol; 2017 Feb; 39(2):1010428317692226. PubMed ID: 28218037
[TBL] [Abstract][Full Text] [Related]
18. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
Zhang CH; Li M; Lin YP; Gao Q
Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231
[TBL] [Abstract][Full Text] [Related]
19. Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers.
Simon N; FitzGerald D
Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27153091
[TBL] [Abstract][Full Text] [Related]
20. Designing immunotoxins for cancer therapy.
Pennell CA; Erickson HA
Immunol Res; 2002; 25(2):177-91. PubMed ID: 11999171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
